| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.01B | 4.77B | 4.48B | 4.37B | 4.02B | 3.71B |
| Gross Profit | 1.79B | 1.69B | 1.57B | 1.54B | 1.43B | 1.29B |
| EBITDA | 887.43M | 852.58M | 772.52M | 652.86M | 709.01M | 616.56M |
| Net Income | 551.32M | 513.67M | 631.25M | 353.40M | 369.45M | 308.28M |
Balance Sheet | ||||||
| Total Assets | 5.36B | 4.99B | 4.81B | 4.59B | 4.98B | 4.87B |
| Cash, Cash Equivalents and Short-Term Investments | 740.76M | 671.61M | 583.67M | 646.76M | 899.46M | 680.44M |
| Total Debt | 1.43B | 1.45B | 1.50B | 1.70B | 2.00B | 1.99B |
| Total Liabilities | 2.82B | 2.60B | 2.56B | 2.76B | 3.08B | 3.04B |
| Stockholders Equity | 2.54B | 2.39B | 2.25B | 1.83B | 1.90B | 1.83B |
Cash Flow | ||||||
| Free Cash Flow | 645.48M | 530.19M | 432.04M | 389.28M | 637.03M | 513.52M |
| Operating Cash Flow | 729.41M | 615.42M | 490.81M | 443.67M | 694.28M | 583.69M |
| Investing Cash Flow | -164.89M | -105.96M | -78.94M | -36.59M | -122.75M | -266.40M |
| Financing Cash Flow | -833.06M | -424.85M | -483.00M | -571.40M | -332.88M | -91.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $6.77B | 27.42 | 25.96% | ― | 14.43% | 29.86% | |
78 Outperform | $7.84B | 14.66 | 22.32% | 1.41% | 7.40% | -14.45% | |
73 Outperform | $12.18B | 33.28 | 10.21% | ― | 14.26% | -15.49% | |
64 Neutral | $5.59B | 14.04 | 35.51% | ― | -1.90% | ― | |
62 Neutral | $2.57B | 7.25 | 12.33% | ― | -4.13% | 2143.48% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
On November 18, 2025, Genpact UK Finco plc and Genpact USA, Inc., subsidiaries of Genpact Limited, completed a $350 million public offering of 4.950% Senior Notes due 2030. The notes are guaranteed by Genpact and Genpact Luxembourg and are intended to be used for general corporate purposes, including potentially repaying existing notes due in 2026. This move is part of Genpact’s strategic financial management to optimize its debt structure and support its ongoing operations.
The most recent analyst rating on (G) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on Genpact stock, see the G Stock Forecast page.